Search 

Celumigen Pharmaceuticals is a California- headquartered seed stage specialty pharmaceutical company in dermatology focused on developing the first FDA-approved topical prescription immunotherapeutic drug for Cutaneous viral warts; a widespread global disease affecting greater than 500MM people in China, and 78% of the world's population. The global markets have seen no approved prescription therapies for HPV, Common warts and no therapies that eradicate this disease on the market or in the pipeline-- we plan to capture and grow this lucrative market. Our therapeutic is a likely 505 (b) 2 FDA designated drug. Our leadership, development and clinical team is a group of world class leaders with deep industry knowledge and unparalleled domain expertise. We have raised a seed round led by industry- leading investors which funded a Proof of Concept study with very positive confirmatory results and data to support our Phases I and Phase II. We are now seeking strategic partnership with a company seeking to support drug development to enhance existing dermatology drug asset portfolios or fund our program through venture capital / partnership.

For more than 120 years, the Trade Commissioner Service (TCS) has been helping Canadian companies navigate international markets. Our trade commissioners in more than 160 cities worldwide can provide you with key business insights and access to an unbeatable network of international contacts. The TCS provides Canadian businesses and organizations with tailored advice to help them enter new markets outside of Canada.

Credevo is a global clinical research and development company that acts as an extended arm of Biopharma companies to facilitate clinical development and product registrations worldwide.

As an investment and management platform established by UK-listed company Cathay International Holdings Limited, Lansen has built up pharmaceutical segment, health segemtn and cosmetic segment. Lansen has been listed in Stock Exchange of Hong Kong Limited (SEHK) on May 7, 2010. Lansen's top products are in rheumatology and dermatology area, and Lansen has established an extensive distribution network, with more than 300 frontline sales staff and more than 1500 distributors. By licensing in promising products at commercial stage and clinical stage, or other cooperation patterns, Lansen plans to expand to more diseases medication market, including rheumaotlogy, dermatology, orthopedics and nephrology.

Founded in 1908, LEO Pharma is an independent, research-based pharmaceutical company, wholly owned by The LEO Foundation and is headquartered in Ballerup, Denmark. LEO Pharma is a leader in medical dermatology and developes, manufactures and markets pharmaceutical drugs for medical dermatology and thrombosis in more than 100 countries globally. We offer patients and physicians highly innovative and well-established products in Psoriasis, Atopic Dermatitis, Eczema, Acne, Rosacea.
LEO Pharma is continuously striving to advance innovation to bring best-in-class and first-in-class medicines in medical dermatology and rare dermatological diseases to create a solid pipeline of assets. LEO Pharma’s mission is to provide people with healthy skin and is has a global dermatology reach employing approximately 6,000 employees worldwide. We serve approximately 92 million patients in 2019 with ambition to serve 125 million patients by 2025.
To realize our vision of becoming the preferred dermatology care partner improving people’s lives around the world, we are constantly looking to collaborate with other companies, Universities to offer patients with therapies that address unmet medical needs in dermatology.

We are keen for In-Licensing Assets for Global and Regional Rights for following: (1) Chinese Rights: innovative (first-in-class or best-in-class) late stage assets (Phase 3 or launched in US, EU or Japan) in medical dermatology or rare dermatological diseases (2) Global Rights: innovative (first-in-class or best-in-class) assets (Pre-clinical through phase III) in medical dermatology or rare dermatological diseases from Asian Biotech companies, Research, and/or academic institutes/universities. (3) VC companies: Who have in their portfolio, companies that have medical dermatology products in their pipeline for China or Global markets (4) Keen to Science and Tech parks in China: Who have companies conducting cutting edge research in medical dermatology
In addition we LEO Pharma has two early stage assets available for partnering.

LEO 142397 (LP0184) is an oral, super selective JAK 1 inhibitor for inflammatory diseases. Product is ready for phase 1 studies. Compound is available for global licensing or acquisition.

LEO 134310 (LP0155) is a SEGRA compound. It is topical, supersoft, non-steroidal Glucocorticoid Receptor (GR) agonist with improved systemic and local safety profile. LP0155 has demonstrated efficacy in clinical phase 1 studies. Compound is available for global licensing or acquisition.

Neuro-Zone, since 13 years, supports drug discovery, drug repurposing and research projects in the fields of inflammation and age-related pathologies.
In particular, we have developed pathology-specific platforms to generate rapid and informative data on efficacy, toxicity, metabolism and mechanism of action, supported by proprietary technologies such as MicroTISSUE (dissecting microenvironment-cell interaction in complex inflammatory scenarios) or MITOS (a comprehensive analytical platform for quantitative analysis of mitochondrial function ).
Our approach enables effective selection and ranking of the most promising candidates per indication.
Moreover, we profile candidates at different level of complexity starting from:
a) pharmacology profiling (GPCR; Ion Channel receptors)
b) identification of biochemical pathways responsible for therapeutic efficacy (transcriptomics)
c) disease modified barrier permeability (BBB and endothelial)

Reistone BioPharma is a clinical-stage biotech company focused on developing innovative medicines in autoimmune and autoinflammatory diseases. We are headquartered in Shanghai, China and have offices in Beijing, China as well in Boston and Chicago, US. Our current pipeline includes 4 small molecules in autoimmune and inflammatory diseases where significant gaps exist. The leading asset, a potent selective JAK1 inhibitor, recently completed global phase 2 trials in China, US and Europe in atopic dermatitis, ulcerative colitis and Crohn’s disease.

Currently we are looking for either partnership to develop the AD and/or UC or CD indications for phase 3 or out-license the global right excluding China market.

We are a late-stage biopharmaceutical company committed to developing and commercializing products to treat rare diseases where there is an unmet medical need.